When Will Lewis arrived at the Washington Post in January 2024, he was received as a potential redeemer. The Post had lost ...

Key benefit: Turn one piece of long-form content into five or more platform-native social assets without starting from scratch, reducing content production time by 40 to 60% while increasing total ...

Discover how continuous compound interest maximizes returns with ongoing calculations. Explore concepts and examples to ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Alphabet (GOOG) reports Q4 2025 earnings today. Wall Street expects $2.61 EPS on $102.35B revenue. Google Cloud hit $15.2B in Q3 with 34% growth. Alphabet projected $91-93B in 2025 CapEx for AI ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS) backing off a plan to offer a knockoff Wegovy pill for as little as $49 ...

The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers for its $49 weight-loss pill, including restricting access to the drug's ingredients ...

Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)’s Wegovy. The oral treatment uses the ...

Share on Pinterest Hims & Hers has withdrawn its low cost compounded weight loss pill after pressure from top U.S. health officials and a major lawsuit. Image courtesy of Novo Nordisk Hims & Hers ...

Hims & Hers' decision to stop offering the $49 version of Novo Nordisk A/S' (NYSE: NVO) Wegovy comes days after the company launched it. "Since launching the compounded semaglutide pill on our ...

Ford posts net loss of $11.1 billion on EV program writedowns Automaker projects $8-10 billion EBIT for 2026 Ford's Q4 revenue of $45.9 billion beat analyst expectations Automaker posts EPS of 13 ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...